PART I . Overview We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (HSV-1), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cells own machinery then transcri...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001711279-26-000016 | EDGAR | 86K words |
| 2025-02-19 | 2024-12-31 | 0001711279-25-000008 | EDGAR | — |
| 2024-02-26 | 2023-12-31 | 0001711279-24-000005 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0001711279-23-000008 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001711279-22-000004 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001711279-21-000006 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001564590-20-009550 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001564590-19-007267 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005252 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-03 | 2026-06-30 | 0001711279-26-000057 | EDGAR | — |
| 2025-11-03 | 2025-09-30 | 0001711279-25-000087 | EDGAR | 19K words |
| 2025-08-04 | 2025-06-30 | 0001711279-25-000077 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001711279-25-000044 | EDGAR | — |
| 2024-11-04 | 2024-09-30 | 0001711279-24-000056 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0001711279-24-000040 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0001711279-24-000020 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001711279-23-000073 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001711279-23-000064 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001711279-23-000029 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001711279-22-000058 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001711279-22-000047 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-03 | 0001711279-26-000058 | EDGAR | — |
| 2026-07-21 | 0001711279-26-000050 | EDGAR | — |
| 2026-02-17 | 0001711279-26-000018 | EDGAR | 4K words |
| 2026-01-12 | 0001711279-26-000008 | EDGAR | — |
| 2026-01-08 | 0001711279-26-000005 | EDGAR | — |
| 2025-12-23 | 0001711279-25-000092 | EDGAR | — |
| 2025-11-03 | 0001711279-25-000088 | EDGAR | — |
| 2025-10-22 | 0001711279-25-000082 | EDGAR | — |
| 2025-08-04 | 0001711279-25-000078 | EDGAR | — |
| 2025-07-25 | 0001711279-25-000071 | EDGAR | — |
167 total filings indexed. 136 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001711279 |
| Ticker | KRYS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.krystalbio.com |
| Listed | 2017-09-20 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KRYS (~200 tokens, structured JSON with cryptographic provenance)